What to monitor during treatment Whether you are on the standard or enhanced protocol, monitoring ensures safety and allows dose adjustments: Weight: Weekly, same time and conditions Energy levels: Daily subjective rating GI symptoms: Daily during titration, weekly at maintenance Blood work (every 3 months): Complete metabolic panel, fasting glucose, HbA1c, liver enzymes, lipid panel, B12, folate Injection sites: Monitor for redness, lumps, or persistent reactions If you notice persistent fatigue despite the niacinamide compound, discuss with your provider whether adjusting your overall approach might be warranted
Enrollment begins with an intake, and billing starts only after a clinician approves
In that way, headache improvement might not only be a consequence of weight loss but also another direct effect of GLP-1-RAs on intracranial pressure [15], which seems to be directly associated with MHD and headache severity [30]
Serious side effects are also slightly more common on tirzepatide
These include the following: Nausea and vomiting (these are common during the first few weeks of starting the medication or when you escalate the dose during the titration phase) Bloating Feeling of fullness or early satiety Stomach ache Constipation Diarrhea (less common) These effects indicate that the medication has started working
In Phase 3 trials, oral orforglipron 36 mg daily produced mean weight loss of approximately 14.7% at 72 weeks comparable to injectable semaglutide 2.4 mg
